Eltrombopag ve ruxolitinib ilaç etken maddelerinin ve impüritelerinin spektroskopik yöntemlerle tanınması ve kromatografik yöntemler ile analitik metot geliştirilmesi ve validasyonu
Thesis Type: Doctorate
Institution Of The Thesis: Ankara University, Sağlık Bilimleri Enstitüsü, ANALİTİK KİMYA ANABİLİM DALI, Turkey
Approval Date: 2024
Thesis Language: Turkish
Student: TİMUR DEMİRHAN
Supervisor: Sibel Ayşıl Özkan
Open Archive Collection: AVESIS Open Access Collection
Abstract:Thanks to the development of science, the cause of cancer and many other diseases is revealed. Many of these diseases are caused by a defect in DNA strings. Since a defect in DNA is passed on from generation to generation, it is of great importance to investigate these diseases. However, the R&D processes of active pharmaceutical ingredients, which are the solution to these diseases, are both very costly and require long-term work. These reasons, on the other hand, increase the prices of drugs and make access to drugs difficult. Therefore, it is very important for countries to carry out their own R&D studies, to produce and purify drugs, to develop analytical methods and to carry out validation studies. Thus, drug prices are reduced and access to drugs is facilitated For this purpose, the active ingredients and impurities of Eltrombopag and Ruxolitinib, synthesized in the API-R&D department of DEVA Holding A.Ş., have been standardized. In this context, these active pharmaceutical ingredients were characterized and their masses were confirmed by mass spectroscopy. Related substances and assay methods of Eltrombopag have been developed. The stability of the related substances and assay methods of Eltrombopag were also proven by a forced degradation study. In addition, a method has been developed that can successfully separate and determine Eltro-1 and its 11 impurities, which is a starting material of Eltrombopag. Also, a method that can selectively determine the active ingredient Ruxolitinib and its chiral impurity (S)-Ruxolitinib has been developed. All developed methods have been validated according to the ICH Q2(R2) guideline and have proven to be selective, accurate, precise, sensitive and stable methods.